The Trump White House abruptly withdrew Dr. Heidi Overton’s nomination to lead the U.S. Food and Drug Administration on November 17, 2026, after it became clear she lacked sufficient support among Senate Republicans. The move came just one day before Overton was set to face a decisive vote in the Senate Health, Education, Labor, and Pensions (HELP) Committee — a sign of continuing intraparty fractures over contentious issues in public health regulation.
Overton, who currently serves as deputy director of the White House Domestic Policy Council, was nominated in August. Her nomination quickly became a litmus test for GOP senators’ views on vaccine policy and tobacco regulation. Committee chair Senator Bill Cassidy reportedly hesitated to support Overton because of concerns that she endorsed breaking up combination vaccines and was not sufficiently independent as a scientific figure. Senator Susan Collins also questioned Overton’s approach to regulating flavored e-cigarettes.
Amid growing objections, the White House confirmed the withdrawal on November 17, citing a lack of congressional backing. The Senate committee had been scheduled to vote on November 18, and the decision forestalled what might have been a divided or failed vote. Cassidy called the withdrawal “odd,” expressing surprise, and suggested that Overton had enough support to pass through both the committee and the full Senate—highlighting inconsistent signals from within the GOP ranks.
The episode underscores a trend: Overton is the latest of several Trump health nominees to withdraw after encountering resistance from Republican senators, following similar developments with previous CDC and surgeon general appointments. Meanwhile, health advocacy organizations such as Make America Healthy Again criticized Overton’s nomination, alleging she obstructed aspects of their agenda.
With the leadership post now vacant, the FDA remains under the temporary stewardship of acting commissioner Kyle Diamantas, whose capacity to lead under federal regulations is inherently limited. There is no immediate word on who the White House might nominate next. As of November 18, the agency continues to navigate critical public health responsibilities with temporary leadership.